NUVL News and Press, Nuvalent Inc.

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor PR Newswire CAMBRIDGE, Mass. , July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company foc...

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 PR Newswire CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharma...

2024-07-11 06:45:01 ET More on Nuvalent Nuvalent: Making Precise Progress In Its Oncology Pipeline Nuvalent: NVL-655 Could Bring Blockbuster Potential Read the full article on Seeking Alpha For further details see: Nuvalent names Henry Pelish as chief sci...

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely target...

2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...

2024-06-24 07:00:00 ET Summary Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resistance, kinase mutations, and CNS-related adverse ev...

2024-06-14 07:15:55 ET Summary Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 and Zidesamtinib showing promise in clinical trial...

2024-06-13 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapi...

2024-05-16 16:18:34 ET More on Nuvalent Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Jefferies starts Nuvalent at buy, cites lung cancer drug candidates Nuvalent lung cancer candidate gets FDA breakthrough therapy status Seeking A...